Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and azacitidine in refractory/relapsed AML
NCT06586099Phase 2Withdrawn
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Oct 2024; status: withdrawn.
02
Drugs
tislelizumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06586099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586099.